RapidAI Acquires Comprehensive Aneurysm Management Innovator and Expands Scope to Include Aneurysm, Extending Its Leadership in Cerebrovascular Imaging

LOS ANGELES, June 06, 2024 (GLOBE NEWSWIRE) -- MedTech Breakthrough , an independent market intelligence organization that recognizes the top companies, technologies, and products in the global digital health and medical technology market, today announced that RapidAI , the global leader in developing Artificial Intelligence (AI) and clinical workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, has been selected as the winner of the “Best Care Coordination Platform” award in the 8th annual MedTech Breakthrough Awards program.The 2024 MedTech Breakthrough Award recognizes the breakthrough innovation of the RapidAI Clinical Platform, a proven solution that provides clinicians from thousands of hospitals in over 100 countries with deep clinical context to make faster and more informed treatment decisions while also enhancing their confidence in diagnosis. By opening up the care pathway through the power of AI and enhanced connectivity, RapidAI transforms the quality of care delivered to patients by facilitating faster, more informed decision-making.“RapidAI’s Clinical Platform moves the needle by pairing together the most clinically validated deep AI algorithms with workflow efficiencies that take the friction out of the healthcare system, making it our ‘Best Care Coordination Platform’ for 2024,” said Steve Johansson, managing director of MedTech Breakthrough. “The workflow efficiencies and connectivity that RapidAI enables ensures that every patient, no matter where they go for care, has access to the most trusted technology and clinical specialists - all while delivering measurable financial and operational impact.”According to the World Stroke Organization (WSO), over 100 million people in the world have experienced a stroke, of which over half will die as a result. On top of this, the WSO estimates 143 million healthy years of life are lost for those who do survive. For stroke patients alone, RapidAI’s technology has been shown to reduce both length-of-stay and non-fatal complications, increase mechanical thrombectomy procedure volume, reduce the number of costly futile transfers, and give radiologists and hospital staff valuable time back through its cutting-edge AI and workflow solution.“We are honored that the RapidAI Clinical Platform has been recognized by MedTech Breakthrough for the care orchestration and workflow efficiencies that it enables,” said Karim Karti, CEO of RapidAI. “By enhancing cross-department collaboration and team communication, the RapidAI Clinical Platform benefits care teams by fostering prompt collaboration and mitigating wasted time and resources

SAN MATEO, Calif.--(BUSINESS WIRE)--RapidAI, the global leader in developing clinically deep Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, today announced that the Food and Drug Administration (FDA) has granted 510(k) clearance for its AngioFlow™ by RapidAI solution. The module delivers perfusion imaging analysis directly within the interventional suite to promote greater clinical confidence, workflow efficiency, and potentially improve patient outcomes. “We are pleased to expand our stroke AI imaging portfolio, the broadest in the industry, to include this new module. With AngioFlow™ by RapidAI, we can now support stroke AI imaging along the entire patient pathway, from the initial non-contrast CT scan all the way to the interventional suite,” said Karim Karti, CEO of RapidAI. “Already registered and used in Japan and Europe, we believe this technology will make a significant difference in the lives of U.S. stroke patients.”